Dene Peters

The Editor of Drugs, the definitive journal of drugs and therapeutics, providing independent and crucial information by leading clinicians and researchers.

[Dene Peters @DrugsJournal]

Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure - leading article by Professor Yun-Fan Liaw, Liver Research Unit, Chang Gung University College of Medicine, Taiwan just published in @DrugsJournal #HepatitisB https://t.co/3rjrcLRw9M

[Dene Peters @DrugsJournal]

Latest issue of @drugsjournal now available online https://t.co/KKa3a2lz4G C. difficile infection, refractory #SLE, autoimmune #epilepsy syndromes, intraperitoneal chemotherapy, Nirsevimab (Beyfortus®) in #RSV and Rezvilutamide (艾瑞恩®) in #prostatecancer

[Dene Peters @DrugsJournal]

In patients with osteoarthritis or back pain, there were no differential risks of incident #Covid_19 diagnosis or COVID-19 hospitalisation for #ibuprofen users compared with other ns-NSAIDs, COX-2i or paracetamol. https://t.co/Of3hLaYhiO

[Dene Peters @DrugsJournal]

Congratulations

[Homma Khosroyani, PhD @HKhosroyani]

My first, first author paper is now published in @DrugsJournal🎉This review discusses current GIST TKI treatments and how our understanding of the molecular mechanisms of the GIST subtypes can inform the development of more successful targeted therapies. https://t.co/Dg9gbtDwy2

[Dene Peters @DrugsJournal]

First original research for the year in @DrugsJournal, "An Integrated Population Pharmacokinetic Analysis for Posaconazole Oral Suspension, Delayed-Release Tablet, and Intravenous Infusion in Healthy Volunteers" from Roger Brüggemann and colleagues https://t.co/MXExqxK0df

[Dene Peters @DrugsJournal]

Just published in the latest issue of @DrugsJournal First Approvals on ozoralizumab (Nanozora®) for rheumatoid arthritis and tremelimumab-actl (IMJUDO®) for a range of malignant tumours https://t.co/ldT56VdHei

[Dene Peters @DrugsJournal]

And now in the news https://t.co/v7nMEbzyQz

[Dene Peters @DrugsJournal]

Great review on gabapentinoids (gabapentin or pregabalin) for pain just published in @DrugsJournal with authors suggesting prescribers should be cautious, particularly with using these agents for a prolonged period #pain https://t.co/Ltr5ucRnhU

[Dene Peters @DrugsJournal]

Great review on gabapentinoids (gabapentin or pregabalin) for pain just published in @DrugsJournal with authors suggesting prescribers should be cautious, particularly with using these agents for a prolonged period #pain https://t.co/Ltr5ucRnhU

[Dene Peters @DrugsJournal]

This very complete article is available open access @DrugsJournal https://t.co/o2Miz3j67Y

[Rosanne Sprute @RosanneSprute]

🔥Brandnew review on new antifungals in clinical trials! @DrugsJournal

Looking forward to see them in clinical use! Sincere thanks @martinhoenigl @CornelyOliver @Amir36520680 @JeffreyJenks5 @jprattes @GRThompsonMD

Fantastic figures from @matteosciart

🔗https://t.co/lTR6WHpvgb

[Dene Peters @DrugsJournal]

The innovative Silicon Valley-based medical journal, Cureus, is now part of the health division of Springer Nature - helping to solve some challenges of open access publishing. https://t.co/ldqm91qgsL

[Dene Peters @DrugsJournal]

Just published in the latest issue of @DrugsJournal First Approvals on Darinaparsin (Darvias®) for peripheral T-cell lymphoma; Teclistamab (TECVAYLI®) for multiple myeloma and Valemetostat tosilate (EZHARMIA®) for non-Hodgkin lymphomas https://t.co/KtF9YxARDZ

[Dene Peters @DrugsJournal]

Just published in @DrugsJournal Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors by Editorial Board members Francesco Locatelli and Lucia Del Vecchio and colleagues https://t.co/LtW137ky3L

[Dene Peters @DrugsJournal]

Adis Insight reports on first approvals just published in @DrugsJournal Lenacapavir (Sunlenca®) for HIV-1 infection and Valoctocogene roxaparvovec (ROCTAVIAN™) for haemophilia https://t.co/x2Pm0b8QBK

[Infectious Diseases and Therapy @InfectDis_Ther]

International validation of a #MRSA risk assessment tool for skin and soft tissue infections https://t.co/VzX5J8WaVW

[Kathy Fraser @AmJClinDerma]

Let Springer Nature support you in the fight against #monkeypox. Explore Springer Nature’s curated collection of articles and book chapter. Additionally, don’t miss out to check the trials related to monkeypox: https://t.co/cs2Jw39IDK

[Drugs Real World Outcomes @DrugsRWOutcomes]

NEW "Trends in the Use of Sedative-Hypnotics, #OPIOIDS, and Neuromuscular Blockers in Hospitalized Patients During the #COVID19 Pandemic"
👉Rapid changes in the use of these #DRUGS were evident during 2020 in Colombia.

Full-text:
https://t.co/tFKw6Hg6pi
#OpenAccess

[Drugs Real World Outcomes @DrugsRWOutcomes]

This #realworld study investigated safety and clinical outcomes of macitentan in a post-marketing study involving Korean patients with pulmonary arterial #hypertension enrolled from 50 medical centers
#OpenAccess

Full-text available here:
https://t.co/PZ78BUmfte

[Martin Hoenigl🇺🇦🇦🇹 @martinhoenigl]

Please visit our

CLINICAL MYCOLOGY @YouTube Channel

posting videos of some of the latest and 🔥🔥 scientific webinars educational presentations in the field.

Never miss an update by
Subscribing here👇
https://t.co/FnKV5WZa6E

[David van Duin @davidvanduin]

#IDTwitter
Do you treat patients? please fill out survey by @AnnetteWestgst & @VanceFowler5 on management of S. aureus bacteremia.

It should take < 15 minutes, is IRB approved, voluntary, and anonymous.
Please RT
 @ABsteward @IdVilchez @ErinMcCreary

https://t.co/E5uvLf0UkM

[Tim Wrightson ☮ @ApplHealthEcon]

Here's a recently published guide for plain language summaries @Emerald_CG @slowcabbage @PECjournal @PatientJournal https://t.co/OfPni7ABsz